INNOVACAP Stock Overview
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Innova Captab Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹473.10 |
| 52 Week High | ₹588.00 |
| 52 Week Low | ₹443.25 |
| Beta | 0 |
| 1 Month Change | 5.24% |
| 3 Month Change | -8.50% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -12.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| INNOVACAP | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 0.8% | 4.8% | 2.1% |
| 1Y | n/a | 19.1% | 45.9% |
Return vs Industry: Insufficient data to determine how INNOVACAP performed against the Indian Life Sciences industry.
Return vs Market: Insufficient data to determine how INNOVACAP performed against the Indian Market.
Price Volatility
| INNOVACAP volatility | |
|---|---|
| INNOVACAP Average Weekly Movement | 3.8% |
| Life Sciences Industry Average Movement | 6.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: INNOVACAP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine INNOVACAP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 1,600 | Vinay Lohariwala | innovacaptab.com |
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also involved in the development, manufacture, and distribution of generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial, erectile dysfunction, anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals.
Innova Captab Limited Fundamentals Summary
| INNOVACAP fundamental statistics | |
|---|---|
| Market cap | ₹27.07b |
| Earnings (TTM) | ₹828.77m |
| Revenue (TTM) | ₹10.60b |
32.7x
P/E Ratio2.6x
P/S RatioIs INNOVACAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INNOVACAP income statement (TTM) | |
|---|---|
| Revenue | ₹10.60b |
| Cost of Revenue | ₹7.44b |
| Gross Profit | ₹3.16b |
| Other Expenses | ₹2.33b |
| Earnings | ₹828.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 14.48 |
| Gross Margin | 29.80% |
| Net Profit Margin | 7.82% |
| Debt/Equity Ratio | 133.8% |
How did INNOVACAP perform over the long term?
See historical performance and comparison